Autres langues Neurogene Inc.

Actions

NGNE

US64135M1053

Temps réel estimé Cboe BZX Autres places de cotation 18:40:46 23/05/2024			Varia. 5j.	Varia. 1 janv.
32,38 ^USD	-0,06 %		-3,80 %	+67,39 %

10/05	Neurogene Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
07/05	Neurogene présente des données d'innocuité favorables issues de l'essai clinique de phase 1/2 de la thérapie génique NGN-401 pour le syndrome de Rett lors de la réunion annuelle de l'Asgct	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates	13/05
Neurogene: Q1 Earnings Snapshot	10/05
Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates	10/05
Neurogene Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05
Neurogene : ASGCT NGN-401 Clinical Safety Poster	07/05
Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meeting	07/05
Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of Ngn-401 Gene Therapy for Rett Syndrome During Asgct Annual Meeting	07/05
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting	22/04
North American Morning Briefing : Stocks Struggle After New Records	22/03
Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates	18/03
Neurogene Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	18/03
North American Morning Briefing : Inflation -2-	15/03
Neurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial	04/03
Neurogene Inc. Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial	04/03
Neurogene to Participate in Upcoming Investor Conferences	29/02
Neurogene Inc. Appoints Donna Cochener as Senior Vice President, General Counsel	21/02
Neurogene Inc. Appoints Julie Jordan as Chief Medical Officer	17/01
Neurogene Names Julie Jordan as Chief Medical Officer	16/01
Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer	16/01
Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer	16/01

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Neurogene Inc.

Actions

NGNE

US64135M1053

Autres langues

Filtres